Overview: Why Immune Complications Matter in Advanced Multiple Myeloma Therapies Chimeric Antigen Receptor (CAR-T) cell therapy and bispecific antibodies (BsAbs) have transformed the treatment landscape for multiple myeloma (MM), offering deep and durable responses for patients with relapsed or refractory disease. Yet, these immune-based therapies also bring new challenges. Immune complications, including impaired humoral and…